Search

Narrow Results
Search
Use my current location
Search

Tag

Number of results found: 17
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 17 results found. Page 1 of 2
    • Clinical Trial
    • Research and Studies

    Keeping Research Close to Northern Nevada

    Clinical research provides agency for our patients navigating a scary diagnosis, and the field has never been stronger in northern Nevada. This strength is thanks in part to the Affiliate Clinical Research Office (ACRO) formed by the 2021 affiliation between Renown Health and the University of Nevada, Reno School of Medicine. Since its creation, the ACRO team has been busy ensuring that community members have access to the latest care options and exceptional experiences as participants in both research and their healthcare. Here are just a few things that set this office apart from the rest. 1. A focus on engagement In 2022, the ARCO team focused on promoting a research culture with patients, clinicians, residents and students by intentionally engaging with healthcare providers, department administrators, internal research team members and leadership. They educated the community with learning materials that emphasized the importance of doing research. This team also worked with front-line staff to raise awareness and excitement about the clinical research options available for Renown Health patients. 2. Meaningful partnerships The most impactful partnership to date is between Renown Health and UNR Med. By identifying opportunities and leveraging resources across institutions, we have maximized our impact and built a solid and sustainable foundation. This gives the people of northern Nevada greater access to new interventions or novel treatments. This team is also investing in the community and national partnerships to provide training opportunities for our research staff and learning opportunities for our medical students. 3. Novel treatments across many disease areas Our research study offerings must reflect the healthcare needs of our community and the expertise of practicing clinicians. The department has over 80 active studies in neurology, pulmonology, oncology, cardiology, pediatrics and disease prevention. The ARCRO team strives to expand care opportunities to allow our community members to stay close to home when seeking care. This year, they will continue exploring our community's unmet healthcare needs by bringing new treatment options to the greater Reno area.

    Read More About Keeping Research Close to Northern Nevada

    • Heart Care
    • Clinical Trial
    • Research and Studies

    Getting to the HEART of Research

    In February, we think about hearts not just in honor of Valentine’s Day but because it is American Heart Association Month. This is a great reminder to focus on our personal cardiovascular health. Renown Health helps patients think about their heart health with our world-class providers and cutting-edge treatments through our Cardiovascular Clinical Trials. “Research serves a vital role in the future care of cardiovascular diseases. Being involved in research will help our medical community to further discover new treatment plans in our quest for life preservation and extension,” Dr. Thomas To, Cardiologist and Researcher at Renown Health. For example, let’s talk about atherosclerosis. When our hearts are healthy, they are a strong muscle that pumps our oxygen-rich blood through our coronary arteries. Over time, cholesterol and fats can build up in our arteries. This is a condition known as atherosclerosis. This type of plaque buildup in the arteries can lead to a heart attack or stroke if not properly managed. If you are experiencing chest pain or discomfort, shortness of breath or pain in areas of the upper body, these can be the warning signs of a heart attack, and you should call 911. One contributing factor to atherosclerosis is elevated lipoprotein(a) levels and the accumulation of cholesterol in the arteries, which increases the likelihood of a heart attack or stroke. Lipoprotein(a) is tested separately from the standard panel that is completed for cholesterol management, and while your total cholesterol levels may be in a healthy range, lipoprotein(a) levels can still be elevated. "Increasingly we are realizing that lipoprotein(a) levels can be used as an important assessment in more carefully delineating an individual's risk of future cardiovascular events and treatment targets" said Dr. Michael Bloch, Lipid Specialist and Researcher at Renown Institute for Heart and Vascular Health. While it is clear that elevated lipoprotein(a) contributes to atherosclerosis, there are currently no approved medications for reducing cardiovascular disease risk through reducing lipoprotein(a) levels. This is why Renown Health’s Research Office is proud to offer a phase III clinical trial, called the OCEAN(a) study, to our patients with elevated lipoprotein(a) levels as a care option for management of their heart disease risk. Our teams of expert providers and researchers are here to support you on your healthcare journey. “I am thrilled to be able to be part of this study and bring opportunities like this to our patients. The highlight of my day is getting to hear life stories from my patients during our study visits,” Lisa Preciado, Primary Clinical Research Coordinator for the OCEAN(a) study said. Join us in raising awareness around American Heart Month by talking to your provider about lipoprotein(a) at your next appointment. At Renown Health, our goal is to make it easy for patients to access clinical research as a care opportunity where patients can access a variety of standard care treatment options for their health condition or choose to participate in a clinical trial. For more information about clinical trial opportunities available to you or to ask any questions, contact the Renown Research Office at Renown-CRD@renown.org or 775-982-3646.

    Read More About Getting to the HEART of Research

    • Fitness
    • Family
    • Reno

    Family-Friendly Bike Trails in Our Region

    Bicycling is a great way to get the whole family moving. We’ve reviewed some family-friendly bike trails that’ll get everyone outdoors for some good, old-fashioned fun on two wheels. During the ongoing COVID-19 (coronavirus) pandemic, it is important to practice physical distancing and wear a mask when it’s impossible to stay six feet away from others. 1. Damonte Ranch Wetland Loop in Reno Duration: 3.1 mile loop. Skill Level: Easy. This paved loop trail is easy to access and has ample wildlife viewing opportunities with plenty of birds and wildflowers in the wetland.  Parking and Trail Access: Start at Damonte Ranch Park and follow the paved trail around the wetland loop. 2. Tahoe East Shore Trail Duration: 5.2 miles out and back. Skill Level: Easy. The Tahoe East Shore Trail closely hugs the shore of Lake Tahoe. The paved trail has mild inclines that make it the perfect adventure for all ages and skill levels.  Parking and Trail Access: Park along State Route 28 in Incline Village near Ponderosa Ranch Road for direct access to the trail.  3. Caughlin Ranch Trails in Reno Duration: 3.5 miles out and back Skill Level: Easy.  This paved trail wanders through the Caughlin Ranch neighborhood and features creeks, wildlife and shade.  Parking and Trail Access: Park along Caughlin Ranch Parkway for easy trail access. 4. Sagehen Creek Trail in Truckee Duration: 6 miles out and back. Skill Level: Intermediate. This dirt loop trail is a short drive from Reno and ends at Stampede Reservoir.  Parking and Trail Access: Park at the marked trailhead off of North Highway 89. 5. Truckee River Trail in West Tahoe Duration: 7.5 miles one way. Skill Level: Intermediate. Looking for a longer trail? This point-to-point trail meanders along the Truckee River through the scenic Olympic Valley.  Parking and Trail Access: Park at the Squaw Valley Village or in Tahoe City. Coordinate with two cars to make the trip one way. What family-friendly bike routes does your family enjoy? We’d love to know!

    Read More About Family-Friendly Bike Trails in Our Region

    • Cancer Care
    • Clinical Trial
    • Research and Studies

    Ovarian Cancer Survivor Shares Decision to Try Clinical Trial

    While there used to be three basic treatment options for cancer -- surgery, radiation and chemotherapy, or a combination of the three -- there's a fourth option: clinical trials. Here, a Renown patient shares her successful battle with ovarian cancer, aided by a clinical trial. Shari Flamm's battle with ovarian cancer began in 2011. She was experiencing prolonged bleeding, irregular thyroid levels and anemia and was scheduled to undergo a hysterectomy. Before the surgery, her gynecologist ran routine tests to check for cancer as a precautionary measure. All tests were negative for cancer, expect her CA 125 test. A CA 125 test measures the amount of the protein CA 125 (cancer antigen 125) in the blood. In some cases, a CA 125 test may be used to look for early signs of ovarian cancer in women with a very high risk of the disease. In most laboratories, the normal level is 0 to 35 units/ml. Flamm's CA 125 level was 121. As Flamm can attest, early diagnosis played a key role in her battle with ovarian cancer. September is Gynecologic Cancer and Ovarian Cancer Awareness Month – an important time to learn the signs, symptoms and risk factors of this type of cancer so your doctor can diagnosis the disease as early as possible. Ovarian Cancer: Round One Despite the elevated CA 125 results, her doctor recommended they move forward with the hysterectomy. But when surgery began, doctors discovered a mass. She had stage 4 cancer. The procedure was halted, the mass was biopsied and she was immediately seen by Dr. Peter Lim of the The Center of Hope. Following diagnosis, Flamm underwent surgery with Dr. Lim to remove the cancer, which had spread to part of diaphragm, spleen, colon and other organs. Three months after surgery, Flamm had recovered enough to start six rounds of chemotherapy in her hometown of Carson City. She continued working at a doctor's office during her treatment, and was grateful for Dr. Lim’s ability to co-manage her care so she could stay close to work and family. “To me, chemo was the scariest part because I didn’t like feeling sick,” Flamm says. Thankfully, her body responded well to the treatments and she was back to the things she loved. “I stated working out at the gym, even if it was only for 10 minutes,” she says. She also stayed positive by spending time with her grandchildren, attending a San Jose Sharks hockey game, going for walks and enjoying concerts. Ovarian Cancer: Round Two In November 2014, Flamm had a cancer check-up. That’s when doctors discovered three cancerous tumors. For this round, Flamm choose another treatment option -- clinical trials at Renown Institute for Cancer. Clinical trials are the studies that test whether drugs work, and inform doctors' decisions about how to treat their patients. Flamm participated in a clinical trial that featured oral-targeted therapy stronger than IV chemotherapy. The hope was for the drug to shrink her tumors, however the result was stabilization -- meaning the lumps weren’t growing or spreading. The best part of the clinical trial, Flamm says, was the constant monitoring. Between the CT scans every six weeks, a heart scan every three months and monthly doctor visits, she was confident that if the cancer started growing or spreading, her healthcare team would catch it right away. For Flamm, the benefits of the clinical trial included less hair loss, less fatigue and more time to focus on what’s important in her life -- her family. “I decided I wasn’t going to be that sick grandma on the couch with cancer,” Flamm says. After taking the oral medication for one year, Flamm developed a rash and discontinued treatment due to discomfort. Clinical Trials, Setbacks and Survival In June 2016, two of the three tumors began to grow and had to be surgically removed. Despite the setback, Flamm was determined to maintain a positive outlook. "You have to stay positive because cancer feeds off anger, depression and stress," Flamm says. Flamm was released to go home with clear margins, meaning the tumors were removed and are surrounded by a rim of normal tissue that does not have cancerous cells. Flamm says her outlook on life has changed drastically since her first cancer diagnosis. “Your whole mentality changes when cancer disturbs your life," Flann says. "The things that weren’t important, are now ever so important. I’m a lot calmer now,” Flamm says.

    Read More About Ovarian Cancer Survivor Shares Decision to Try Clinical Trial

    • Clinical Trial
    • Research and Studies

    What Does It Mean to Participate in a Clinical Trial?

    Participating in a clinical trial is voluntary and a personal choice. Clinical trials are research studies that involve people and are an important part of patient care. What is a clinical trial?  Clinical trials are research studies that involve people, and they are an important part of patient care. There are several different types of clinical trials; some are designed to understand trends in a disease or identify better ways to diagnose a condition, while others determine if a new treatment is safe and works when treating, improving or preventing a health condition. There are over 400,000 clinical trials currently being conducted in the United States, and even more across the world. This includes health conditions such as heart failure, cancer, Parkinson’s Disease, respiratory conditions like COPD, common infections, cystic fibrosis, and many more. Clinical trials lead the healthcare industry to new discoveries that contribute to reliable and exact care, improving healthcare quality and saving lives. Clinical trials are conducted by a team of researchers, including doctors, pharmacists and clinical research coordinators. These research teams are highly skilled in their specialty areas, often providing traditional patient care and seeing research patients in the same day. These teams are responsible for making sure the clinical trial is completed correctly, and their patients are their top priority. Why should I consider participating in a clinical trial? Participating in a clinical trial is voluntary and a personal choice. There are many reasons why patients decide to get involved in clinical research. While many clinical trials are designed for patients who have a certain health condition, many studies also ask healthy volunteers to contribute in order to compare health outcomes. Clinical trials are also for patients at all different stages of their diagnosis. Depending on the specific study, the patient may receive access to a new cutting-edge treatment before it is widely available. When patients join a clinical trial, the research team becomes a health partner dedicated to their health and well-being. When patients join a clinical trial, they make an informed decision in their healthcare by weighing all available options in addition to routine treatments. Research participants know that they are contributing meaningfully and helping other patients like them. Where can I find more information about clinical trials at Renown Health? Renown Health’s mission is to make a genuine difference in the health and well-being of the communities we serve. Renown’s clinical trial portfolio offers leading care options to patients in northern Nevada, close to home, in a variety of specialties. Contact the Renown Clinical Research Office for more information on clinical trials available to you!

    Read More About What Does It Mean to Participate in a Clinical Trial?

    • Research and Studies
    • Clinical Trial

    How the UNR Med Affiliation Impacts Renown's Clinical Research

    The University of Nevada, Reno School of Medicine (UNR Med) and Renown Health affiliated in June of 2021. First Integrated Health System The University of Nevada, Reno School of Medicine (UNR Med) and Renown Health affiliated in June of 2021. This agreement established Nevada’s first integrated health system with missions in education, patient care, and clinical research. While there was extensive media coverage regarding the historic partnership in general, there is less information regarding the important impact to the community. In terms of clinical research, the potential benefits are endless. The School of Medicine has a very successful program in molecular bio sciences. That means they have a plethora of brilliant minds working on the smallest components of life related to body systems and disease. With the affiliation, there is a distinct opportunity to bridge some of these important findings happening on campus and translate them into care protocols for the patients seen in the community. Making connections between the cellular basics to the physical manifestations of conditions is a key opportunity of the affiliation. Additionally, cooperative funding models for projects that fit in the translational research bucket are available to these researchers. Renown and UNR Med are poised to provide potentially cutting-edge treatments with bench to bedside research. Expanding Clinical Trials Perhaps the most important outcome of the affiliation is access to novel treatments via clinical trials. In the coming years, Renown and UNR Med will work to expand their clinical trial portfolio in an effort to provide a clinical trial option for many diseases in addition to standard of care. This endeavor will allow patients to make an informed choice about their healthcare. With novel treatments available right here in Reno, people won’t have to travel to other research institutions for similar care. This eases a tremendous potential burden on patients and families alike navigating complex illnesses like cancer. The affiliation is exciting and provides many opportunities for clinicians (present and future) and the community. Renown's Clinical Research Office is thrilled to be a part of this historic time and are enthusiastic to communicate our successes and opportunities to the community. We sincerely look forward to contributing to the vision of “a healthy Nevada.”

    Read More About How the UNR Med Affiliation Impacts Renown's Clinical Research

    • Thursday, Feb 11, 2021

    Renown Children's Hospital Announces 2021 Children's Miracle Network Champion Child Ambassador

    Despite numerous medical challenges, Emmalee Sutton is a determined, bright and outgoing 14-year-old with a joy for life and passion for helping others. Renown Children’s Hospital and Children’s Miracle Network Hospitals (CMNH) are excited to announce Emmalee Sutton as the 2021 Champion Child Ambassador. A fighter from a very young age, 14-year-old Emmalee has been a source of hope and inspiration to everyone she meets, never letting her medical challenges slow her down.  A video introducing Emmalee and her journey can be found here.  Emmalee was diagnosed with autoimmune hepatitis at age 2, and she has endured a long road of illnesses and hospitalizations since. She also has Addison’s disease, which means her body under-produces critical hormones. She had her gallbladder removed at age 8, port surgery at 13, and has received several liver biopsies over the years.  Over time, heavy steroid use has stunted her growth — at 14 years old, she is 49 inches tall. It has also caused extreme weight gains and losses. She also faces daily issues with her calcium, potassium and sodium levels. Due to her lack of immunities, she is unable to attend school in-person but is on the home/hospital program through the Washoe County School District. Despite Emmalee’s medical challenges, her sheer joy and spark for life remains untouched.  “I am so honored to be chosen as the 2021 Champion Child Ambassador and represent all the kids at Renown Children’s Hospital. I hope my story can inspire other young patients to believe in themselves,” said Emmalee. “It can be hard dealing with health challenges, but I always think about those who have it worse than me. Instead of complaining about the things I can’t do, I celebrate all the things I can do.” “We can all learn from Emmalee’s enthusiasm, determination and positive outlook,” said Tony Slonim, MD, DrPH, President & CEO of Renown. “She has never met an obstacle too great or faced a challenge too difficult, and she effortlessly inspires others to view life through that same lens. Emmalee has already touched so many hearts here at Renown, and as our 2021 Champion Child Ambassador, her impact is sure to be incredible.”  Emmalee loves to talk to and help other children, especially when she visits Renown Children’s Hospital for treatments. One of her favorite things to do in the hospital is visit with other patients and try to make them feel better.  “Emmalee is very patient with all the doctors she sees, the medications she takes and the frequent lab testing and blood draws she receives,” said her mom, Ann Sutton. “She always remains positive and comforts those who think they are hurting her. This makes her quite the beloved patient at Renown Children’s Hospital!” Emmalee enjoys spending time with her four dogs and rabbit, and she also has an affinity for frogs, lizards and fish. She loves to sew and crochet, and for the past six years, she has held the title of top cookie-seller in her Girl Scout troop. When Emmalee grows up, she wants to be a pediatric nurse so she can help other kids who are going through what she has experienced. Her ultimate goal in life is to make the world a better place in many ways.  “From the moment I met Emmalee, I knew she was a champion,” said Kiemmy Thai, MBA, Foundation Manager of Children's Hospital at Renown. “Her courage and perseverance inspire so many pediatric patients with hope when they need it most. Her smile is contagious, and her words of wisdom at such a young age will have a great impact on our community. We are excited to work with Emmalee and help bring out the champion in others.” Emmalee will serve as Renown Children’s Hospital’s CMNH Champion Child for the next two years, acting as the face of the hospital in the community and sharing her heartwarming and inspiring story. Supporting Champions Like Emmalee Funds from the Children's Miracle Network Hospitals’ have helped purchase equipment for several of the subspecialists Emmalee needs to see. Additionally, Emmalee has benefited from equipment that CMNH has funded during her in-patient stays, such as distraction machines, iPads and CinemaVision goggles. You can support local champion children like Emmalee by visiting renown.childrensmiraclenetworkhospitals.org.   About Renown Children’s Hospital Renown Children’s Hospital is the only dedicated children’s hospital in northern Nevada, and offers a variety of programs and services designed specifically to care for the community's families. It has the region’s only Children’s ER and Pediatric ICU. Renown Children’s Hospital is the only hospital affiliated with Children’s Miracle Network Hospitals (CMNH) in the region and local CMN Hospitals' programs and events directly benefit children in the Truckee Meadows. It is also the only hospital in the region affiliated with CHA (Children’s Hospital Association). For more information, visit here. About Children’s Miracle Network Hospitals Children’s Miracle Network Hospitals® raises funds and awareness for 170 member hospitals that provide 32 million treatments each year to kids across the U.S. and Canada. Donations stay local to fund critical treatments and healthcare services, pediatric medical equipment and charitable care. Since 1983, Children’s Miracle Network Hospitals has raised more than $7 billion, most of it $1 at a time through the charity's Miracle Balloon icon. Its various fundraising partners and programs support the nonprofit's mission to save and improve the lives of as many children as possible. Find out why children's hospitals need community support, and learn about your member hospital, at CMNHospitals.org and facebook.com/CMNHospital.

    Read More About Renown Children's Hospital Announces 2021 Children's Miracle Network Champion Child Ambassador

    • Wednesday, Apr 27, 2022

    Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

    Released in partnership with the Desert Research Institute: New research from the Healthy Nevada Project® finds that a confirmed diagnosis does not always result in changes to patient care. Presenting individuals with potentially life-altering health information doesn’t mean the individuals – or their healthcare providers – will act on it. Follow-up education and conversations about actionable care plans with patients and their doctors are key next steps, according to new research from the Healthy Nevada Project.  The Healthy Nevada Project is a genetic screening and research project that launched in 2016 as a partnership between DRI and Renown Health. The project now has more than 50,000 participants, with genetic sequencing provided by Helix.  Between September 2018 and September 2020, the Healthy Nevada Project successfully notified 293 participants that they were genetically at risk for hereditary breast and ovarian cancer syndrome, Lynch syndrome, or familial hypercholesterolemia – three common genetic conditions known collectively as the Centers for Disease Control and Prevention (CDC) Tier 1 conditions. In a study published today in Frontiers in Genetics, Healthy Nevada Project scientists looked at the impact that notifying a patient of a positive finding for a CDC Tier 1 condition had on the care that the patient received in the months and years that followed.  According to their results, among the 293 Healthy Nevada Project participants who were notified of their genetic risk of a CDC Tier 1 condition, 71 percent of participants with electronic health records shared their findings with healthcare providers. However, only 30 percent of the electronic health records for these patients contained documentation of the genetic diagnosis, and only 10 percent of examined patients experienced a possible change in care after receiving the results of their genetic screening.  “The Healthy Nevada Project was implemented with a ‘hands-off’ approach where the participants receive their findings and decide with whom and when to share those findings. The findings were not automatically added to their electronic health records,” said Dr. Gai Elhanan, health data scientist at DRI and co-lead author of the study. “What we’re learning now is that to ensure that important genetic findings are integrated into the care journey it is important to make their inclusion into the electronic health records part of the study.” This study builds on previous Healthy Nevada Project research published in Nature Medicine demonstrating the importance of screening for CDC Tier 1 conditions, which affect about one in 75 individuals and can be mitigated or even prevented from developing into disease when detected early. This study found that as many as 90 percent of the CDC Tier 1 cases are missed by clinical providers during normal clinical care screenings and examinations. During the current study, the Healthy Nevada Project scientists found that 19 percent of studied participants had already developed one of the CDC Tier 1 conditions, and thus would have potentially benefited from earlier notification about their condition. The study team hopes that their findings will encourage individuals in Nevada to obtain genetic testing for these relatively common conditions. Even if individuals are older or have already suffered from diseases related to these conditions, testing could also prove beneficial to siblings, children, and grandchildren who may also be at risk and who could subsequently be screened in the event of a positive finding. The study team also encourages informing health care providers of the importance of incorporating genetic diagnoses into the pharmaceutical (for example, for Familial Hypercholesterolemia) and treatment advice given to patients.  “As a result of this analysis, the clinicians at Renown Health and the Healthy Nevada Project researchers have made significant changes, including obtaining informed consent from participants to report positive findings from their genetics reports directly into their electronic medical record,” said Daniel Kiser, M.S., assistant research scientist of data science at DRI and co-lead author of the study. “This will help both participants, their clinical providers, and the whole state maximize the long-term benefits of the Healthy Nevada Project voluntary population-based genetic screening.” Additional information: The full text of the study,  Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record, is available from Frontiers in Genetics: https://www.frontiersin.org/articles/10.3389/fgene.2022.866169/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Genetics&id=866169.  This project was funded by Renown Health, the Renown Health Foundation, and the Nevada Governor’s Office of Economic Development. Study authors included Gai Elhanan (DRI), Daniel Kiser (DRI), Iva Neveux (DRI), Shaun Dabe (Renown Health), Alexander Bolze (Helix), William Metcalf (DRI), James Lu (Helix), and Joseph Grzymski (DRI/Renown Health). For more information on the Healthy Nevada Project® or to request genetic screening, please visit: https://healthynv.org/ About DRI The Desert Research Institute (DRI) is a recognized world leader in basic and applied environmental research. Committed to scientific excellence and integrity, DRI faculty, students who work alongside them, and staff have developed scientific knowledge and innovative technologies in research projects around the globe. Since 1959, DRI’s research has advanced scientific knowledge on topics ranging from humans’ impact on the environment to the environment’s impact on humans. DRI’s impactful science and inspiring solutions support Nevada’s diverse economy, provide science-based educational opportunities, and inform policymakers, business leaders, and community members. With campuses in Las Vegas and Reno, DRI serves as the non-profit research arm of the Nevada System of Higher Education. For more information, please visit www.dri.edu. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision making. Learn more at www.helix.com.

    Read More About Study Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening Result

    • Friday, Feb 17, 2023

    Renown Children's Hospital Announces 2023 Children's Miracle Network Champion Child

    Renown Children’s Hospital and Children’s Miracle Network Hospitals (CMNH) are excited to announce Shaylie Edwards as the 2023 Champion Child. A fighter from a young age, seven-year-old Shaylie has overcome many challenges in her short life. In 2019 when she was three, Shaylie was hit by a car while using a crosswalk with her father. She was admitted to the Wilbur D. May Pediatric Intensive Care Unit (PICU) at Renown Children’s Hospital and stayed there for three months. A video introducing Shaylie and her journey can be found here.  Shaylie’s mom, Erica Edwards reports that as a result of the accident, Shaylie has been treated by Renown Children’s Hospital physicians, nurses and team for a broken neck in two places, a broken jaw in two places, a fractured sacrum, a broken femur and three small brain bleeds. She has been in outpatient therapy for the last three years and continues making strides daily. “Shaylie’s perseverance, dedication and joy inspires all of us at Renown Children’s Hospital,” said Kristina Deeter, MD, MBA, FAAP Physician-in-Chief, Renown Children’s Hospital and Chair of Pediatrics, University of Nevada, Reno School of Medicine,” (pictured right with Shaylie). “It has been an incredible joy to witness her progress and to care for Shaylie and her family. We are thrilled she has been chosen to share her story with the world.”  The New England Journal of Medicine cites preventable injuries as the number one leading cause of death among children. This includes motor vehicle accidents, firearm injuries, drowning, poisoning, burns and suffocation. According to Safe Kids Worldwide, an average of 155 children under the age of 10 die every year as a result of pedestrian injury, with 64% of those involving motor vehicles. Across the U.S., due to distracted driving, a pedestrian is killed every two hours and injured every seven minutes. Most drivers feel they can safely take their eyes off the road for 0-2 seconds, but a car can travel the length of a football field in 5 seconds at 55 MPH. Shaylie’s family and the team at Renown Children’s Hospital urge drivers to be fully aware and eliminate distractions while driving.  “We were in the Wilbur D. May PICU for three months and the first five days were very iffy. We did not know if she would come out of her coma, but Shaylie is a fighter. The care team at Renown Children’s Hospital made me feel at home and like we were all going through this together,” said Shaylie’s mother, Erica Edwards. “Shaylie’s recovery was a collaboration between doctors, nurses, and our family. Together we were there to support Shaylie, who has proven to us repeatedly that she has a greater purpose in life.” “It was heartwarming to meet Shaylie and her family,” said Dr. Brian Erling, MBA, CEO of Renown Health. “Shaylie is truly a champion! She and her family have faced life's unanticipated events with strength and resilience. Despite the struggles, they have carried on with hope and determination. They find joy in life every day and inspire us all. We have much to learn from their example.” Through Renown Children’s Hospital, Shaylie and 100,000 area children now have access to more than 60 pediatricians, including those specializing in adolescent medicine; anesthesia; cardiology; craniofacial surgery; dentistry; ear, nose and throat conditions; emergency medicine; endocrinology; gastroenterology;  general pediatrics; hospitalist medicine; intensive care; neonatology; neurology; oncology; ophthalmology;  orthopedics; psychiatry; psychology; pulmonology; surgery; urology and other subspecialties previously lacking in the community, as well as a pediatric emergency room, pediatric ICU and contemporary healthcare services at Renown Children’s Hospital. Prior to 2016, about 30% of all pediatric patients had to leave northern Nevada to receive the specialty care they needed. Now, thanks to donor support, Renown estimates that 97% of all pediatric patients and their families can receive both general and specialty pediatric care locally. The next nearest children’s hospital in the state is 7 hours or 438 miles away in Las Vegas. Renown Children’s Hospital is proud to be the only CMNH hospital in northern Nevada, one of only 170 premier children’s hospitals in North America. Shaylie will serve as Renown Children’s Hospital’s CMNH Champion Child for the next year, shining as the face of the hospital in the community and sharing her inspiring story. Renown Health Foundation oversees the local CMNH programs and its fundraising. One hundred percent of all funds raised by CMNH partners stay local to support children and families in our community. Your generous support affords much-needed items to help our littlest patients cope with the potential stressors associated with hospitalization and illness. To donate, visit www.renown.org/donate. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is hiring people like you. Visit us at www.renown.org/careers.  About Children’s Miracle Network Hospitals Children’s Miracle Network Hospitals® raises funds and awareness for 170 member hospitals that provide 32 million treatments each year to kids across the U.S. and Canada. Donations stay local to fund critical treatments and healthcare services, pediatric medical equipment, and charitable care. Since 1983, Children’s Miracle Network Hospitals has raised more than $7 billion, most of it $1 at a time through the charity's Miracle Balloon icon. Its various fundraising partners and programs support the nonprofit's mission to save and improve the lives of as many children as possible. Find out why children's hospitals need community support, and learn about your member hospital, at www.renown.org/CMNH.

    Read More About Renown Children's Hospital Announces 2023 Children's Miracle Network Champion Child

    • Sunday, Jan 01, 2023

    Renown Welcome Area's First Baby of 2023

    Meet Eleazar, the first baby born in the Reno-Sparks area in 2023 Reno's first baby of 2023 was born in the Labor and Delivery Childbirth Center at Renown Regional Medical Center. Gricella Grajeda gave birth to Eleazar Grajeda at 1:05 a.m. on Sunday, Jan. 1, 2023. Baby Eleazar weighed 5 pounds, 3.4 ounces and was the first 2023 birth at any of the region's hospitals. Baby Eleazar is also welcomed to the world by Yesinia Valazquez. More than 4,040 babies were delivered at Renown Health in 2022. Renown Health offers exceptional family-centered care with complete prenatal services designed for the health and well-being of every patient and their new baby. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 6,500 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®

    Read More About Renown Welcome Area's First Baby of 2023

    • Thursday, Jul 11, 2019

    Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

    Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

    Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

    • Tuesday, Jun 16, 2020

    Renown Celebrates Pride Month and LGBTQ+ Communities with Love

    Rainbow lights illuminate Renown’s iconic “LOVE” sculpture, and powerful employee stories shared during Pride Month. Reno, Nev. (June 16, 2020) –In celebration of Pride Month and Reno’s LGBTQ+ communities, Renown’s LOVE sculpture, a one-ton, welded aluminum artwork with letters 10-feet tall and eight-feet wide, will be illuminated by rainbow LED lights throughout the month of June. LOVE is located at Renown Regional Medical Center’s main entrance at 1155 Mill Street in Reno, Nev. and visible to vehicular and pedestrian traffic along the Mill Street and Ryland Street corridors. Dr. Tony Slonim, president and CEO of Renown says, “At Renown, we are proud to support our LGBTQ+ communities. During Pride Month and beyond, we are honored to offer an inclusive, safe environment for our staff and patients—one that celebrates diversity in all its forms. The LOVE sculpture has already brought a bright light into our world, and I look forward to the joy it will bring to everyone who gets to see it in rainbow colors.”    In commemoration of Pride Month, Renown is committed to highlighting some of the LGBTQ+ individuals who make up a portion of its 7,000 employees. Sean Savoy, Renown’s manager of spiritual care, shares how his experiences as a gay man positively affect his career in spiritual healing and the compassion he shows others.     "The foundation of spiritual care is compassion – being with people in need by caring, supporting, and showing empathy, and promoting a sense of well-being,” said Savoy. Being a member of the LGBTQ+ community informs that deep sense of compassion and empathy in a very special and unique way.I have found the intersectionality of my gay and spiritual selves has been a blessing in my life."  Created by artist Laura Kimpton and fabricated by Jeff Schomberg, the LOVE sculpture first appeared at Burning Man in 2019. Thanks to a partnership with non-profit Artown, the sculpture debuted at Renown in April of 2020, and since served as a symbol of hope and determination for hospital staff, patients and community members amid the COVID-19 pandemic. Generous donors and the Renown Health Foundation funded the sculpture’s instillation.   ###   About Renown Health  Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. For more information, visit renown.org. Media Contact: Public Relations M: 775-691-7308 E: news@renown.org

    Read More About Renown Celebrates Pride Month and LGBTQ+ Communities with Love

Number of results found: 17
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 17 results found. Page 1 of 2